Biotech Showcase™ 2025: Innovation Insights for the Year Ahead

Biotech Showcase™ 2025 Opens the Year with More than 3,000 Attendees, 340+ Presenting Companies, 1,020+ Investors and 85+ Members of the Media

SAN FRANCISCO--(BUSINESS WIRE)--Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 17th year with record-breaking investor and partner meetings. 6,700+ meetings facilitated in-person and online connections while more than 340 company presentations and 28 panels delivered new value to in-person attendees and helped to shape the 2025 outlook for biotechnology.

“We welcomed more than 3,000 attendees, including 1,026 investors and 86 media representatives this year in a testament to the resilience and ingenuity of the biotech sector,” said Sara Jane Demy, Founder and CEO of Demy-Colton. “With so many company presentations, a robust Seed Showcase, and a new program track, TechBio, Biotech Showcase has become the number one destination of choice for both innovators and private investors.”

New programming this year included the TechBio Showcase, which explored the innovations and trends shaping biotech. Biotech Showcase discussions spanned a broad range of topics, including advancements in cell and gene therapy, enhancing longevity, collaboration opportunities in the Asia Pacific region, trends in biotech, financing, investment and business development partnerships.

“The quality of both the speakers and company presentations at this year’s Biotech Showcase conference was absolutely outstanding,” said Anna Chrisman, Global Managing Director, EBD Group.

More than 100 speakers shared their expertise and varying perspectives, including:

• Grace Colón, CEO & Co-Founder, Inaya Therapeutics, BIO Executive Committee Member
• Olga Danilchanka, Partner, MRL Ventures Fund, Merck
• Alessandro Falcone, Head, JLABS Singapore, Johnson & Johnson
• Andrei Georgescu, CEO & Co-Founder, Vivodyne
• James Healy, Managing Partner, Sofinnova Investments
• William Ho, CEO, In8bio
• David Jenkins, SVP, Head of External Innovation and Research, Ipsen
• Konstantina Katcheves, SVP, Innovation Medicines Business Development and Acquisitions, Teva Pharmaceuticals
• Adam Pearson, Chief Strategy Officer, Astellas Pharma
• Nabiha Saklayen, CEO & Founder, Cellino Biotech
• Scott Whitaker, President & CEO, AdvaMed
• Alice Zheng, Partner, Foreground Capital
• And members of the media, including Alex Philippidis (GEN), Adam Bluestein (Fast Company), Allison DeAngelis (STAT News), Ron Leuty (San Francisco Business Times), Kyle LaHucik (Endpoints News), and David Ewing Duncan.

“I’m encouraged by the very strong enthusiasm and engagement here about the industry’s prospects for 2025, as well as the highly positive feedback from investors and partnering companies about the program and the companies they were able to connect with,” Demy added.

Registered attendees can access recorded program sessions and company presentations on-demand anytime through the partneringONE® platform.

Stay tuned for updates on next year’s Biotech Showcase by visiting www.biotechshowcase.com.

About Demy-Colton

Demy-Colton is a premier life sciences events organization committed to connecting industry leaders and fostering partnerships that advance life sciences innovation globally. Demy-Colton’s portfolio includes Biotech Showcase™, BioFuture™, and the Biotech CEO Summits in Europe and California, as well as virtual events designed to keep life sciences professionals connected year-round.

For more information, please visit www.demy-colton.com.

About EBD Group

EBD Group’s overriding mission is to help collaborations get started across the life sciences value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life sciences markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings.

Today our events (BIO-Europe®, BIO-Europe Spring®, Biotech Showcase™, ChinaBio® Partnering Forum, Asia Bio Partnering Forum and BioEquity Europe) annually attract more than 15,000 senior life sciences executives who engage in over 60,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.

For more information, please visit www.ebdgroup.com.